Nmn And Memory Preservation
Quick Read NMN is a molecule your body converts into NAD+, a chemical that powers your cells’ energy generators and
Subscribe to the distribution list, to get regular updates on supplement research for health,
🧠 NeuroBright Our evidence-based brain supplement formulated from 1.7M research papers
Homocysteine is an amino acid your body produces from protein. When B vitamins (folate, B12, and B6) are low, homocysteine builds up in your blood, and even moderately elevated levels have been linked to brain damage, shrinkage in memory areas, and increased dementia risk. Research spanning two decades shows that people with elevated homocysteine have up to 150% higher dementia risk compared to those with lower levels.
B vitamin supplements reliably lower homocysteine and appear to slow brain shrinkage and cognitive decline in people with cognitive impairment. A recent analysis of 17 trials involving over 5,200 older adults found a small but real improvement in brain function with B vitamin supplementation. However, taking folate alone (without other B vitamins) was linked to increased dementia risk, while taking it as part of a full B complex was safe.
We still don’t have large prevention trials in healthy people, and it’s unclear whether lowering homocysteine reverses damage once dementia has started. Getting your homocysteine level tested is simple and inexpensive. Taking a daily B complex containing folate, B12, and B6 is safe, cheap, and supported by evidence as a practical step for brain health in middle age and beyond.
Verdict: Elevated homocysteine is a genuine, modifiable dementia risk factor, and taking a comprehensive B complex supplement appears to be a sensible, low-cost habit for protecting brain health over time.
What if there were a measurable, modifiable risk factor for dementia, one that shows up in a standard blood test, responds to a safe and inexpensive intervention, and has been studied for over two decades, and yet most people in their 40s and 50s have never heard of it? That’s not a hypothetical. It’s the story of homocysteine, and it may be one of the most overlooked conversations in brain health today. From the 1.77 million research papers Vitacuity has analysed, fifteen were selected for this topic, and together, they paint a picture that is too important to ignore.
Let’s start with the basics. Homocysteine is an amino acid, a natural byproduct of protein metabolism. Your body produces it constantly as it processes methionine (an amino acid found in meat, eggs and dairy). Under normal circumstances, your body clears homocysteine efficiently, recycling it back into useful compounds. But this clearance process depends almost entirely on three B vitamins: folate (B9), vitamin B12, and vitamin B6 [11].
When these vitamins are in short supply, which becomes increasingly common as we age, homocysteine builds up in the blood. This state is called hyperhomocysteinaemia, and even moderately elevated levels (above 11 µmol/L) have been linked to a cascade of damaging effects in the brain [6].
How does high homocysteine actually harm the brain? Several mechanisms appear to be at work. It is directly neurotoxic, meaning it can damage and kill neurons [15]. It disrupts the blood-brain barrier, impairs cerebrovascular circulation, and appears to accelerate brain atrophy, including shrinkage in memory-critical areas like the hippocampus [7]. It also promotes the formation of neurofibrillary tangles, one of the hallmarks of Alzheimer’s pathology [7]. In short, chronically elevated homocysteine seems to age the brain faster.
The particularly important thing to understand is that homocysteine doesn’t spike dramatically and suddenly. It creeps up gradually over years, often sitting in what looks like the “normal” range on standard blood tests, while still doing measurable damage. Levels above 11 µmol/L are described in the scientific literature as concerning, yet many labs only flag a result as abnormal above 15 µmol/L [6]. That gap matters enormously.
The epidemiological evidence here is among the strongest we have for any modifiable dementia risk factor. Evidence grade: Strong, multiple prospective studies and meta-analyses in humans.
A 2018 International Consensus Statement, authored by a group of independent experts who reviewed twenty years of literature, concluded that elevated plasma homocysteine is a modifiable risk factor for cognitive decline, dementia, and Alzheimer’s disease in older people [6]. This wasn’t a single study, it was a structured review applying the Bradford Hill criteria, the same framework used to establish that smoking causes lung cancer.
The numbers are striking. Across a variety of clinical studies, the relative risk of dementia in elderly people with moderately raised homocysteine ranges from 1.15 to 2.5, meaning up to a 150% increased risk compared to those with lower levels [6]. The population attributable risk, the proportion of dementia cases that could theoretically be linked to elevated homocysteine, ranges from 4.3% to 31% [6]. Even at the conservative end, that is a substantial public health burden.
Prospective data (studies that follow people over time before disease develops) consistently show that elevated homocysteine precedes cognitive decline, it’s not simply a consequence of dementia already developing [12]. The relationship appears to be dose-dependent: the higher the homocysteine, the greater the cognitive risk [15]. And crucially, levels that sit within what many doctors would consider “normal” can still predict meaningful acceleration in brain ageing.
Here’s where the story gets more nuanced. Evidence grade for homocysteine lowering: Strong. Evidence grade for cognitive benefit: Promising, with important caveats.
The good news first. B vitamin supplementation, specifically combinations of folate, B12, and B6, is highly effective at lowering homocysteine levels. This has been demonstrated repeatedly and consistently. In a 2006 open-label study of 58 patients with Alzheimer’s disease, vascular dementia, and mild cognitive impairment, B vitamin supplementation produced a significant decline in homocysteine concentrations in all patient groups within just one month (all p<0.01) [10].
A 2021 study of 97 patients with mild cognitive impairment or various forms of dementia (plus 54 elderly controls) confirmed that B vitamin levels, specifically B1, B6, B12, and folate, were measurably lower in Alzheimer’s patients compared to cognitively healthy older adults [14]. Homocysteine was already elevated at the mild cognitive impairment stage, before full dementia developed, and correlated negatively with levels of all three B vitamins [14]. In other words: low B vitamins, high homocysteine, earlier cognitive decline.
The harder question is whether lowering homocysteine with B vitamins translates directly into cognitive improvement, and this is where the evidence becomes genuinely mixed.
The most persuasive intervention data comes not from cognitive tests but from brain imaging. Evidence grade: Promising, small but well-designed RCTs with objective biological endpoints.
A 2016 review by leading researchers in this field noted that trials in high-risk subjects which had taken into account baseline B vitamin status showed a slowing of cognitive decline and, importantly, a slowing of atrophy in critical brain regions [7]. This is significant because brain atrophy (shrinkage) is an objective, measurable biological endpoint, not a subjective questionnaire score. When B vitamins slow brain shrinkage, that’s a concrete physiological effect.
The 2018 International Consensus Statement corroborated this, concluding that intervention trials in elderly people with cognitive impairment show that homocysteine-lowering treatment with B vitamins “markedly slows the rate of whole and regional brain atrophy and also slows cognitive decline” [6]. The word “markedly” is not one researchers use lightly in a consensus document.
A 2011 review similarly noted that recent B vitamin supplementation trials had demonstrated “a slowing of brain atrophy and improvement in some domains of cognitive function” [15]. These findings, particularly around brain volume preservation, remain some of the most compelling biological evidence that the homocysteine-B vitamin pathway is not merely a correlation, but a causal mechanism worth intervening on.
For a cleaner statistical overview of the evidence, a 2025 systematic review and meta-analysis is particularly valuable, and particularly honest. Evidence grade: High certainty for a small benefit, this is the most rigorous recent analysis available.
This analysis searched PubMed, Embase, PsychInfo, Scopus, and the Cochrane Library for randomised controlled trials (RCTs), identifying 17 eligible trials involving 5,275 participants aged 60 and over, each lasting at least 26 weeks [3].
The initial pooled finding showed a small to moderate improvement in global cognitive function (Hedges’ g = 0.423; 95% CI: 0.188 to 0.657), but with very high heterogeneity between studies (I² = 92.71%), meaning the trials were producing quite different results [3]. This heterogeneity is important: it tells us the intervention doesn’t work the same way in every population or context.
When the researchers performed a meta-regression and removed statistical outliers and single-blinded studies, both known sources of inflated effect sizes, the picture became cleaner: a small but real benefit (Hedges’ g = 0.110; 95% CI: 0.034 to 0.186), with negligible heterogeneity (I² = 15.39%) and a GRADE rating of high certainty [3]. In plain English: when you strip out the noise, you get consistent evidence of a modest positive effect on cognitive function in older adults. The effect didn’t differ significantly between people with intact cognition, mild cognitive impairment, or dementia [3], suggesting B vitamins may be relevant across the cognitive spectrum.
One finding from the research deserves particular attention, because it carries a practical implication for anyone considering supplementation. Evidence grade: Promising/Conflicted, large observational data but from a non-randomised study.
A 2024 analysis of 466,224 UK Biobank participants found that taking folate or folic acid supplementation *alone*, without other B vitamins, was associated with a significantly *higher* risk of Alzheimer’s disease (HR = 1.34; 95% CI: 1.06–1.69) and vascular dementia (HR = 1.61; 95% CI: 1.21–2.13) [5]. Folate supplementation alone was also associated with reduced volume in the hippocampus and amygdala, precisely the brain regions most vulnerable in Alzheimer’s disease [5].
Crucially, however, when folate was taken in combination with other B vitamins, these detrimental associations disappeared entirely, the risk of both Alzheimer’s and vascular dementia was not significantly different from the non-supplementing group [5].
This is an important nuance. Folate in isolation may mask a B12 deficiency (a well-known interaction in nutritional medicine) or disrupt the balance of the methyl cycle in ways that become harmful without the full B vitamin complement. The practical message is clear: if you’re going to supplement for homocysteine management, a comprehensive B complex is the approach supported by this evidence, not folate alone [5].
One genuine scientific debate worth flagging is whether homocysteine is a *cause* of brain damage or merely a *marker*, a signal that something else (perhaps oxidative stress, or B vitamin deficiency itself) is doing the real harm. Evidence grade: Conflicted, ongoing scientific debate, but with practical consensus emerging.
A 2006 review raised this question directly, noting that it remained unclear whether elevated homocysteine has a direct pathophysiological role or is simply reflecting an underlying process [12]. A 2013 review added an interesting wrinkle: in the cardiovascular domain, lowering homocysteine with B vitamins did *not* appear to reduce atherosclerotic lesions or cardiovascular events, suggesting that in that context, homocysteine may indeed be more marker than cause [13]. Yet the same review concluded that, in contrast, folate and B vitamin administration *does* appear to reduce homocysteine and antagonise mechanisms favouring neurodegeneration, suggesting the brain pathway may be genuinely different from the cardiovascular one [13].
The 2025 debate paper in the Journal of Alzheimer’s Disease explicitly notes that the Lancet Commission on Dementia Prevention failed to identify raised homocysteine as a modifiable risk factor “despite considerable evidence,” calling for a formal debate on the matter [1]. This is a significant scientific disagreement at the highest level.
So does the cause-versus-marker distinction matter practically? The 2018 Consensus Statement makes a compelling argument that it doesn’t, at least for the individual. B vitamins are safe, inexpensive, and address the most likely underlying cause of elevated homocysteine (B vitamin deficiency) regardless of whether homocysteine itself is the agent of damage. If the B vitamin deficiency is the real culprit, supplementing corrects it. If homocysteine is independently harmful, supplementing lowers it. Either way, the intervention is the same [6].
Honesty matters here, and there are genuine gaps in this evidence.
Timing may be everything. Several reviews note that many B vitamin intervention trials were “poorly designed by including subjects unlikely to benefit during the trial period” [7]. Most trials have enrolled people who already have established cognitive impairment or dementia. The evidence for B vitamins *preventing* dementia in cognitively healthy adults remains limited, we simply haven’t run enough large, long-term prevention trials in people with elevated homocysteine but intact cognition [6][7].
The 2017 meta-analysis found no MMSE improvement. A smaller meta-analysis of four RCTs found that while B vitamin supplementation reliably reduced homocysteine (pooled difference = -3.625 µmol/L; p<0.001), it did not produce a significant improvement on the Mini-Mental State Examination (MMSE) in patients with existing Alzheimer's disease or dementia [8]. This is an important null result, and it suggests that once significant neurodegeneration has occurred, lowering homocysteine may not reverse it. The implication is that earlier intervention is likely more important.
We don’t fully understand inflammation’s role. The 2006 open-label study found that while B vitamins lowered homocysteine, they had no effect on neopterin, a marker of immune activation and inflammation, suggesting that brain inflammation in dementia patients continues even when homocysteine is brought under control [10]. This raises the question of whether homocysteine and neuroinflammation are parallel processes requiring separate interventions.
Optimal doses remain unclear. The 2025 meta-analysis found no consistent dose-response relationship across trials [3]. We know supplementation works, but we don’t yet have a definitive “optimal dose”, a gap that future trials should address.
The UK Biobank finding is observational. The large folate-alone finding comes from a non-randomised observational study [5]. While the sample size (466,224 participants) is impressive, confounding factors can never be fully excluded. RCT confirmation would strengthen this finding considerably.
Here’s what a sensible, well-informed person should take from all of this.
Homocysteine is a real, measurable risk factor for brain ageing. The evidence for this, spanning twenty years of epidemiological data, prospective studies, imaging trials, and international consensus, is genuinely substantial [6][7]. It’s not mainstream medical conversation yet, but that’s a failure of health communication, not a failure of the evidence.
Should you get your homocysteine tested? Ideally yes, it’s a standard blood test that most GPs can order, and it costs very little. If your level is above 11 µmol/L, you have something concrete to act on. But here’s the practical reality: even if testing isn’t accessible or convenient for you right now, the intervention (a B complex supplement) is the same either way. There is no meaningful downside to taking a comprehensive B vitamin complex. B vitamins are water-soluble, your body excretes what it doesn’t need. Excess is cleared in urine. Toxicity from B complex supplements at normal doses is essentially not a clinical concern [6].
What should you take? The evidence points clearly to a combination of folate (B9), B12, and B6, not folate alone [5][6]. A comprehensive B complex covers all bases, is safe, and is genuinely cheap. This is exactly the kind of low-cost, low-risk intervention that the Consensus Statement authors say “should not be underestimated” in public health terms [6].
When should you start? Earlier is almost certainly better. The data suggest that homocysteine may be elevated and actively contributing to neurodegeneration well before any cognitive symptoms appear [14]. Waiting until cognition is already declining may mean the window for maximum benefit has passed [7].
The bottom line: take a B complex daily, ensure it contains folate (not just folic acid, ideally, but folic acid in the context of a full B complex still appears safe [5]), B12, and B6. Keep your protein intake reasonable (excess methionine from very high protein diets raises homocysteine). And if you can, get your homocysteine level checked, it’s one of the few dementia risk markers that is genuinely under your control.
This is not a miracle. It’s not a cure. But it may be one of the most sensible, evidence-backed, low-cost habits a person in their 40s, 50s or 60s can adopt for long-term brain health.
[1] Concerning the debate about homocysteine, B vitamins, and dementia (2025). DOI: 10.1177/13872877251350297 | https://pubmed.ncbi.nlm.nih.gov/40551597/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12284325/
[2] Neurovascular Correlates of Cobalamin, Folate, and Homocysteine in Dementia (2023). https://pubmed.ncbi.nlm.nih.gov/37980672/
[3] Efficacy of B Vitamin Supplementation on Global Cognitive Function in Older Adults: A Systematic Review and Meta-analysis (2025). DOI: 10.1093/nutrit/nuaf155 | https://pubmed.ncbi.nlm.nih.gov/40966571/
[4] Discussing “Associations of Folate/Folic Acid Supplementation Alone and in Combination With Other B Vitamins on Dementia Risk and Brain Structure” (2024). https://pubmed.ncbi.nlm.nih.gov/38949211/
[5] Associations of Folate/Folic Acid Supplementation Alone and in Combination With Other B Vitamins on Dementia Risk and Brain Structure: Evidence From 466 224 UK Biobank Participants (2024). https://pubmed.ncbi.nlm.nih.gov/38029284/
[6] Homocysteine and Dementia: An International Consensus Statement (2018). https://pubmed.ncbi.nlm.nih.gov/29480200/
[7] Homocysteine, B Vitamins, and Cognitive Impairment (2016). DOI: 10.1146/annurev-nutr-071715-050947 | https://pubmed.ncbi.nlm.nih.gov/27431367/
[8] Efficacy of Vitamin B Supplementation on Cognition in Elderly Patients With Cognitive-Related Diseases (2017). https://pubmed.ncbi.nlm.nih.gov/28248558/
[10] Homocysteine but not neopterin declines in demented patients on B vitamins (2006). https://pubmed.ncbi.nlm.nih.gov/16988797/
[11] Homocysteine and cognitive function in elderly people (2004). DOI: 10.1503/cmaj.1031586 | https://pubmed.ncbi.nlm.nih.gov/15477631/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC522658/
[12] Elevated plasma homocysteine levels: risk factor or risk marker for the development of dementia and Alzheimer’s disease? (2006). https://pubmed.ncbi.nlm.nih.gov/16917147/
[13] Lowering homocysteine levels with folic acid and B-vitamins do not reduce early atherosclerosis, but could interfere with cognitive decline and Alzheimer’s disease (2013). https://pubmed.ncbi.nlm.nih.gov/23224755/
[14] Association Between Homocysteine and Vitamin Levels in Demented Patients (2021). DOI: 10.3233/JAD-201481 | https://pubmed.ncbi.nlm.nih.gov/33998538/
[15] Homocysteine: a biomarker in neurodegenerative diseases (2011). https://pubmed.ncbi.nlm.nih.gov/21388339/
This article is for informational purposes only and does not constitute medical advice. Food supplements should not be used as a substitute for a varied and balanced diet and healthy lifestyle. If you are pregnant, breastfeeding, taking medication or have a medical condition, consult your doctor before taking any supplement. These statements have not been evaluated by the Food and Drug Administration (FDA) or the Medicines and Healthcare products Regulatory Agency (MHRA). This product is not intended to diagnose, treat, cure, or prevent any disease.
Quick Read NMN is a molecule your body converts into NAD+, a chemical that powers your cells’ energy generators and
Quick Read Some symptoms often blamed on aging, like brain fog and poor memory, may actually stem from B vitamin
Get notified about new articles